focus -WSS

focus

author：comprehensive 2025-10-02 22:26:40 - browse：587

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Health care court cases: Humana, Sutter, Novant

WSS

5 takeaways from STAT's examination of Zynex Medical

5 takeaways from STAT's examination of Zynex Medical

Cheap, fast test for Zika and dengue could cost just $1

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Report captures long Covid’s disabling effects and policy challenges

ALS patient reclaims some autonomy thanks to wearable 'robot'

hotspot

focus

entertainment

Psychedelics group wrestles with new pharma identity

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Alkermes shareholders re

The woman behind the Dana Farber

State Dept. review finds Biden bears some blame for Afghanistan failures

The woman behind the Dana Farber

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AI models in health care face new federal disclosure requirements

In Memoriam: Notable people who died in 2023

Supreme Court wrestles with OxyContin maker's bankruptcy deal

leisure time

Cigna wins case to block Amy Bricker's move to CVS

Pregnancy discrimination could be enabled by AI

5 takeaways from STAT's examination of Zynex Medical

Pfizer plans to depart BIO

Chemotherapy shortages won’t get better under Biden’s latest plan

Cheap, fast test for Zika and dengue could cost just $1

focus

leisure time

focus

explore